TCG Labs-Soleil
Josh Lichtman serves as the Chief Scientific Officer and Co-Founder at TCG Labs-Soleil since June 2023, contributing to large molecule compound and target discovery in the realm of metabolic disease treatment. Prior to this role, Lichtman held various positions at NGM Biopharmaceuticals from March 2015 to May 2023, including Vice President of Research, Associate Director of Bioinformatics, and Senior Scientist in Bioinformatics. Additional experience includes an internship focused on gut microbiota discovery, as well as research roles at Stanford University, Synthetic Genomics, and Hanson Technologies. Academic credentials include a Ph.D. in Chemical and Systems Biology from Stanford University, complemented by a certificate in Innovation and Entrepreneurship from Stanford's Graduate School of Business and a B.S. in Biochemistry and Molecular Biology from Dickinson College.
TCG Labs-Soleil
At TCG Labs-Soleil, we are establishing a pioneering venture-biotech model in collaboration with The Column Group. Our mission is to efficiently translate scientific insights into therapeutic solutions for patients facing serious diseases. Our approach integrates a dedicated venture fund (TCG Labs) with an evergreen R&D hub led by top-tier scientists (Soleil). This creates a powerful ecosystem forming and overseeing independent portfolio companies, each dedicated to single-asset biologic programs, guiding them from ideation to clinical proof of concept and positioning them for strategic partnerships and transformative medical advancements.